First-line lorlatinib achieves durable systemic and intracranial response in EML4-ALK positive large-cell neuroendocrine carcinoma: a case report with DNA/RNA fusion discordance
Background Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the current first-line standard of care for advanced non-small cell lung cancer (NSCLC) harboring EML4-ALK rearrangement. However, ALK rearrangements are rarely identified in pulmonary large-cell neuroendocrine carcinoma (LCNEC), and clinical evidence supporting ALK TKI directed therapy in this population remains limited. Case presentation We report a 35-year-old man diagnosed with advanced large-cell neuroendocrine carcinoma (LCNEC) carrying an EML4-ALK rearrangement. First-line lorlatinib resulted in rapid systemic tumor regression and complete intracranial response. At the data cutoff, the patient's progression-free survival had not been reached at 13.47 months with good tolerability. DNA-based next-generation sequencing identified two ALK rearrangements, whereas RNA-based sequencing detected only the canonical EML4-ALK rearrangement transcript. Testicular pain occurred during treatment and improved after dose modification; however, a definitive causal relationship could not be established. Conclusion This case report demonstrates the efficacy of lorlatinib as first-line therapy for large-cell neuroendocrine carcinoma with ALK rearrangement. The observed DNA/RNA fusion discordance also illustrates the complementary roles of DNA- and RNA-based testing in interpreting complex genomic rearrangements.
Authors
- Qiangzhong Pi (ORCID: https://orcid.org/0000-0001-8944-4182)
- Peiqiang Liang (ORCID: https://orcid.org/0000-0002-0411-3083)
- Hu Luo
Institutions
- Army Medical University (CN)
- Southwest Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fmed.2026.1944174
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00